The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009Aldehyde Dehydrogenase Activators as Novel Drugs For the Treatment of PD
Objective/Rationale:
The accumulation of at least two toxic products in the brain called DOPAL and 4HNE results in death of neurons that are implicated in Parkinson’s Disease (PD). We identified a... -
Rapid Response Innovation Awards, 2009Enzymes that Catalyze for Alpha-synuclein Ubiquitination and Degradation
Objective/Rationale:
A characteristic feature of Parkinson’s disease (PD) is the buildup of the protein, alpha-synuclein, and overproduction of this protein can trigger PD. Therefore, it is important... -
Rapid Response Innovation Awards, 2009Serum Biomarkers for Parkinson's Disease
Objective/Rationale:
The immune system appears to play an important role in the progression of Parkinson’s disease, and immunotherapy may offer an approach to slow or stop disease progression. The... -
Rapid Response Innovation Awards, 2009Small Molecule Inhibitors of Alpha-synuclein Assembly and Toxicity
Objective/Rationale:
We will test a novel drug candidate that blocks formation of the toxic aggregates of the protein alpha-synuclein, which are believed to cause Parkinson’s disease (PD). Our drug... -
Rapid Response Innovation Awards, 2009Glycine Uptake Inhibitors as Potential Enhancers of Dopaminergic Axon Regeneration
Objective/Rationale
An important goal in Parkinson’s disease therapy is to restore the loss of the dopaminergic innervation of the striatum. Cell culture data from our lab indicate that activation of... -
Rapid Response Innovation Awards, 2009Multi-site Coordinated Reset Stimulation of the Subthalamic Nucleus
Objective/Rationale:
Current deep brain stimulation (DBS) does not take advantage of the latest discoveries of Parkinson’s disease (PD) pathophysiology which may explain some of its limitations...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.